What this is
- How it works
- How it works isn't classified yet
- Tested for
- Psoriatic Arthritis (PsA)
- Main trialPhase 2
- “This study will investigate if the study medicine FT2109 can treat symptoms of active Psoriatic Arthritis (PsA). This study assesses the safety and efficacy of FT2109 in adult participants with active PsA who may or may not have been treated previously with advanced therapy and who may be on stable background therapy. In this study, researchers will look at different doses of FT2109 compared to placebo (a treatment with no active study drug in it). Researchers will try to learn if at least one of the study doses of FT2109 works better than placebo to treat PsA symptoms.”In the company’s words, NCT07869134 on ClinicalTrials.gov
Other drugs for Psoriatic Arthritis (PsA)
- SHR0302Hengrui · Phase 3
- SonelokimabMoonLake Immunotherapeutics AG · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- ZasocitinibTakeda · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
Coming up1
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Oct 2027 | Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026